Abstract: A system and method for verification of nasogastric tube (NGT) placement is provided. A fiber optic light guide includes a proximal end with a light source connection and a distal end having a light emitting tip. The light guide is constructed and arranged for insertion into a lumen of the NGT. A stop that prevents the distal end of the light guide from exiting a distal end of the NGT. The stop is adapted to engage a connector on the proximal end of the NGT. The light emitting tip can comprises a radial emitter. The light source can emit light at approximately 650 nm with an output power of approximately 30W. The stop is located so that the distal end of the light guide is positioned at an offset from the distal end of the NGT when the stop engages the proximal end of the NGT.

Abstract: The present invention relates to a process for preparing a composition for washing keratin materials, in particular human keratin fibres such as the hair, comprising the mixing of an anhydrous solid composition comprising one or more anionic surfactants and one or more amphoteric or zwitterionic surfactants with water, followed by agitation and then leaving to stand the aqueous composition obtained from this mixing.

Abstract: A cosmetic having an excellent effect of solidifying sebum is to be provided. A cosmetic is used that includes low aspect ratio zinc oxide having an average aspect ratio of less than 4 and high aspect ratio zinc oxide having an average aspect ratio of 4 or more, wherein an amount of the high aspect ratio zinc oxide blended is 1 to 80 mass % with respect to a total amount of the high aspect ratio zinc oxide and the low aspect ratio zinc oxide.

Abstract: There is provided a composition for teeth desensitization. The composition comprises from 1 to 15 wt. % of suspended crystals of oxalic acid potassium salt dihydrate having a size of from 50 nm to less than 1000 nm. The composition comprises from 0.5 to 10 g/L of NaOH and has a pH of less than 2.

Abstract: The present invention relates to a composition for treating keratin fibers such as hair, comprising: (a) at least one hydroxy acid or salt thereof; (b) at least one cationic polyamino acid; and (c) water, wherein the amount of the (b) cationic polyamino acid(s) is 0.2% by weight or more, preferably 0.3% by weight or more, more preferably 0.5% by weight or more, and even more preferably 0.8% by weight or more, relative to the total weight of the composition. The present invention can smoothen keratin fibers.

Abstract: Disclosed is the use of certain methyl-fluoro-hydroxybenzoates as flavor and fragrance constituents and for imparting a wintergreen odor note to a consumer product. Furthermore the use of certain methyl-fluoro-hydroxybenzoates as complete or partial replacement for methyl salicylate is disclosed.

Abstract: The present invention relates to a composition, in the form of an O/W emulsion, comprising: (a) at least one oil; (b) at least one first polyglyceryl fatty acid ester having a C6-C22 fatty acid residue; (c) at least one second polyglyceryl fatty acid ester having a C24-C32 fatty acid residue; (d) at least one fatty alcohol; (e) at least one gemini surfactant; and (f) water, wherein the weighted average of HLB values of the (b) first polyglyceryl fatty acid ester and the (c) second polyglyceryl fatty acid ester is between 8 and 11, and the weight ratio of the amount of the (b) first polyglyceryl fatty acid ester/the amount of the (c) second polyglyceryl fatty acid ester is more than 15 and less than 35. The composition according to the present invention includes a polyglyceryl fatty acid ester, but it is stable and can provide no sticky feeling or a reduced sticky feeling as well as a non-greasy feeling or smooth feeling.

Abstract: The invention relates to a process for dyeing keratin fibres, preferably the hair, comprising the application to said keratin fibres of a composition comprising at least one oxidation dye base chosen from para-phenylenediamine derivatives of formula (I), their addition salts, their solvates and/or the solvates of their salts, in which R is chosen from a (C1-C4)alkoxy(C1-C4)alkyl radical and a C1-C4 hydroxyalkyl radical, at least one compound chosen from N,N-dicarboxymethylglutamic acid, one of its salts and mixtures thereof and a chemical oxidizing agent. The process may comprise the step of mixing a dyeing composition comprising the oxidation dye base and the N,N-dicarboxymethylglutamic acid compound with an oxidizing composition comprising one or more chemical oxidizing agents and applying the obtained mixture to the keratin fibres. A multi-compartment device comprises a first compartment containing the dyeing composition and a second compartment containing the oxidizing composition.

Abstract: A composition comprising: (i) 0.01 to 10 wt % of a branched or dialkyl cationic conditioning surfactant; selected from Structures 1, 2 and 3, as further defined herein; (ii) 0.01 to 10 wt % of a linear cationic conditioning surfactant; (iii) 0.1 to 10 wt % of a linear fatty material; (iv) 0.1 to 5 wt % of a structurant; and (v) a particulate benefit agent selected from conditioning actives; the composition having molar ratios of branched or dialkyl cationic conditioning surfactants (i) to linear fatty material (ii) in the range of from 1:10 to 1:1 and a molar ratio of branched or dialkyl cationic surfactant (i) to linear fatty material (iii) in the range of from 1:20 to 1:1. The composition results in improved particulate benefit agent deposition onto bleached hair.

Abstract: An agent for oxidatively changing the color of keratin fibers, such as human hair, may include at least one complexing agent of the general formula (I); at least one activator from the group of amino acids, protein hydrolyzates, and radical scavengers; and at least one oxidant.

Abstract: The present invention relates to a shaping tool (10B) for keratin fibers comprising a gripping member (12) and a shaping member (14) comprising a base body (18) and ribs (20). The base body (18) is integral with the gripping member (12), and has two lateral edges (24) and a free distal edge (26) opposite the gripping member (12). Each rib (20) protruding from the base body (18), the ribs (20) also extending parallel to one another and to a transverse axis (Y) and defining grooves (22) between them, each rib (20) having a constant height along the transverse axis (Y) between the two lateral edges (24), the free distal edge (26) of the base body (18) extending parallel to the transverse axis (Y).

Abstract: The present invention provides compositions comprising an active ingredient, with a combination of at least one multi-tail surfactant, at least one cationic polymer and at least one anionic surfactant, different from the at least one multi-tail surfactant.

Abstract: A cosmetic composition for providing a matte foundation may be provided, that includes a mattifying filler, a colorant, a hydrocarbon-based oil, a hydrocarbon-based emulsifier, water, and UV filter system consisting of an organic hydrophobic UV filter, an organic water-soluble UV filter, and an inorganic UV filter. The mattifying filler may consist of a silica aerogel and optionally a modified starch, amorphous silica, a clay, and/or a silicone elastomer. The organic hydrophobic UV filter may consist of octyl salicylate, and the cosmetic composition may be free of other organic hydrophobic ultraviolet filters. The organic water-soluble ultraviolet filter may consist of 2-phenylbenzimidazole-5-sulfonic acid (PBSA), and the cosmetic composition may be free of other organic water-soluble ultraviolet filters. The inorganic UV filter may consist of UV-grade titanium dioxide, and the cosmetic composition may be free of other inorganic ultraviolet filters.

Abstract: The present application relates to a sunscreen or daily care composition comprising bis-ethylhexyloxyphenol methoxyphenyl triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazine), titanium dioxide, and zinc oxide.

Abstract: A subject of the present invention is a cosmetic composition comprising 6-hydroxybenzomorpholine of formula (II), hydroxyethyl-3,4-methylenedioxyaniline of formula (III) and oxidation bases. The present invention also relates to a process for dyeing keratin fibres, such as the hair, wherein the composition as described previously is applied to said fibres. Another subject of the present invention is the use of the composition according to the invention for the cosmetic treatment of keratin fibres such as the hair.

Abstract: The present invention relates to a process for coating keratin materials, which consists in applying to said materials a coating agent formed by hydrogen bonding interaction of at least one polyphenol X comprising at least two different phenol groups with at least one compound Y including at least two functional groups Gy, which may be identical or different, which are capable of forming at least two hydrogen bonds with said phenol groups of said polyphenol X. More particularly, the process is intended for making up keratin materials.

Abstract: The present disclosure relates to a release composition comprising a protein and an active agent, wherein the active agent is released when in presence of an electrolyte solution. A kit and an article comprising the release composition of the present-subject matter are also encompassed.

Abstract: A formulation for the care of damaged hair is provided, comprising: a vehicle; a silicone; and a deposition aid, wherein the deposition aid is a cationic dextran polymer, comprising a dextran base polymer functionalized with quaternary ammonium groups; wherein the dextran base polymer has a weight average molecular weight of 50,000 to 3,000,000 Daltons; wherein the quaternary ammonium groups include (i) a quaternary ammonium group of formula (II) bound to a pendent oxygen on the dextran base polymer (ii) a quaternary ammonium group of formula (III) bound to a pendent oxygen on the dextran base polymer wherein is pendent oxygen on the dextran base polymer; wherein X is a divalent linking group; wherein each R2 is independently selected from a C1-4 alkyl group; wherein each R3 is independently selected from a C1-4 alkyl group; and wherein each R4 is independently selected from a C5-20 alkyl group.

Abstract: The present invention relates to a composition, comprising (a) at least one modified starch; (b) at least one C13-C15 acid; (c) at least one clay; and (d) at least one amphoteric surfactant, wherein the weight ratio of the amount of the (d) amphoteric surfactant/the amount of the (b) C13-C15 fatty acid is 0.5 or more, preferably 0.6 or more, and more preferably 0.7 or more. The composition according to the present invention can be rinsed off from a keratin substance such as skin and can leave an enhanced deposition of clay on the keratin substance after rinsing off the composition from the skin.

Abstract: Disclosed in this specification is a composition comprising polymer hyaluronic acid nanoparticles. In the present disclosure, the polymer hyaluronic acid is micronized to facilitate skin penetration without depolymerization of the polymer hyaluronic acid, and may be stably comprised in a formulation. In addition, the micronized polymer hyaluronic acid comprised in the composition of the present disclosure penetrates the skin and then is neutralized to pH of the skin and expanded in size again, which can provide excellent benefits for moisturizing the skin and improving skin elasticity.

Abstract: A nail composition including a base composition and a dispersion of acrylic polymer particles. The dispersion of acrylic polymer particles is a dispersion of C1-C4 alkyl (meth)acrylate polymer particles stabilized with a stabilizer in a hydrocarbon oil, where the stabilizer is selected from the group consisting of: isobornyl (meth)acrylate homopolymers and statistical copolymers of isobornyl (meth)acrylate and of C1-C4 alkyl (meth)acrylate. The nail composition does not comprise a UV-curable material.

Abstract: The present invention relates to a cosmetic composition, preferably a hair composition, comprising one or more amino silicones, one or more non-amino silicones and one or more non-ionic associative polymers. The invention also relates to a cosmetic treatment process for keratin materials, in particular for caring for and/or conditioning the hair, using said cosmetic composition.

Abstract: Provided are water-resistant and/or photoprotective compositions including: (a) an aqueous phase including from 0% to 99.9% by weight of the composition, based on the total weight of the composition; (b) an oil phase including from 0% to 99.9% by weight of the composition, based on the total weight of the composition; (c) an active sun block agent; and (d) a micronized, non-solubilized wax including 0.1% to 10% by weight of the composition, based on the total weight of the composition; wherein the wax has a D50 particle size of 1 to 100 ?m, and a melting point of at least 70° C.; and wherein the composition includes at least 50% by weight of at least one of the aqueous phase or the oil phase. Uses of the compositions, and methods utilizing the compositions, are also provided.

Abstract: An oral care product that may suppress adhesion of bacteria floating in the oral cavity to the teeth by not using an antibacterial ingredient or by reducing the concentration of the antibacterial ingredient and a material contained in the product are produced. A composition for oral cavity care contains a Codium algae extract, and contains, as an active ingredient, a protein fraction contained in the Codium algae extract and having a molecular weight of 5000 or more.

Abstract: A method for reducing the appearance of hyperpigmented skin is disclosed. The method can include topically applying to hyperpigmented skin of a person a composition that includes at least one of, at least two of, or all three of (i) an effective amount of Schinus terebinthifolius seed extract, (ii) an effective amount of a mixture comprising Ptychopetalum olacoides bark/stem extract, Pfaffia paniculata root extract, and Trichilia catigua bark extract, and/or (iii) an effective amount of a mixture comprising Himanthalia elongata extract and Undaria pinnatifida extract. Topical application of the composition can reduce the appearance of the hyperpigmented skin.

Abstract: The invention relates to a drug delivery system for contraception including a steroidal estrogenic compound, a steroidal progestogenic compound or a combination thereof for the purposes of contraception in a subject, and provides for an ultra-low dose delivery of a steroidal estrogenic compound which minimizes or eliminates a burst release effect. The invention also relates to a method of contraception using the drug delivery system and method of manufacturing the drug delivery system.

Abstract: The present invention relates to high concentration ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast, which are suitable for intravitreal or other ocular administration to injection sites internal or external to the eye and orbit. The compositions can comprise about 2% to about 5% w/v of roflumilast, a viscosity agent, a tonicity agent, a buffer agent, a surfactant, and water. The pharmaceutical compositions are stable with little to no impurities and can be injected from a 27 Gauge or 30 Gauge syringe with minimal force, resulting in therapeutic levels of pharmaceutical in relevant tissues for the ocular surface, anterior compartment, vitreous/posterior compartments, and tissues or chambers surrounding the eye.

Abstract: The present invention relates to an orodispersible pharmaceutical solid dosage form comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof a pharmaceutically acceptable polymer suitable for forming a matrix with rasagiline or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, wherein rasagiline or a pharmaceutically acceptable salt thereof is trapped within the matrix, and wherein said dosage form exhibits a dissolution profile according to which (i) after 2 minutes at pH=7.0, less than 12% w/w of the rasagiline relative to the total rasagiline content of the dosage form is dissolved, and (ii) after 15 minutes at pH=1.2, more than 75% w/w of the rasagiline relative to the total rasagiline content of the dosage form is dissolved, and (iii) after 40 minutes at pH=1.

Abstract: The oral cavity is an ideal-site for small molecule, nutrient/nutraceutical delivery to the central nervous system (CNS) and systemic circulation due to the highly-vascularized, oral mucosa, near-neutral pH conditions, close proximity to the brain, and avoidance of gastric degradation and the first-pass effect. The rich-blood supply of the oral mucosa and “sticky”, mucoadhesive properties of this novel, saccharide-based, delivery system allows for the efficient absorption of small molecules across several highly-vascularized surfaces including the gingival, sublingual, soft-palatal, and buccal mucosa. Herein, I introduce a novel, saccharide-based, food-form, palatable, easy-to-administer, oral delivery system that attaches to these four, highly-absorptive surfaces for a longer contact-duration than current orally-available formulas resulting in greater, small molecule bioavailability, and a more rapid, therapeutic effect.

Abstract: A composition and method is described herein. The method includes administrating a composition capable of generating molecular hydrogen to an individual, the method comprising: co-administering food and a dose or doses of the composition to the alimentary canal of the individual, wherein the composition comprises glucomannan, xanthan gum, magnesium metal powder, an organic acid, excipients, or any combination thereof. The method also includes administering the composition formulated for oral delivery wherein the administration induces satiety/weight loss, exercise endurance, anti-inflammatory effects, or any combination thereof. The method also includes administering the composition enclosed in a capsule, as a powder composition, as a hydrogel, or any combination thereof.

Abstract: An aerosolizable liquid formulation for inhalation includes one or more active pharmaceutical ingredients dissolved in a solvent. The one or more active pharmaceutical ingredients includes a vasodilator active pharmaceutical ingredient and, optionally, non-vasodilator active pharmaceutical ingredient.

Abstract: The present application provides a compound dry powder inhalant, comprising baicalin, ambroxol hydrochloride, L-leucine and phosphate, wherein based on a mass of the compound dry powder inhalant, L-leucine accounts for 0-50%, phosphate accounts for 15-35%, and a total mass of baicalin and ambroxol hydrochloride accounts for 15-85%, and wherein a mass ratio of baicalin to ambroxol hydrochloride is 1:0.2 to 2. The compound dry powder inhalant has a Dv90?5 ?m. The drug combination of baicalin and ambroxol hydrochloride can effectively reduce inflammation and oxidative damage in lung tissue, alleviate pulmonary edema and histopathological changes, and reduce pulmonary dysfunction and pulmonary fibrosis.

Abstract: The present disclosure relates to an inhalable pharmaceutical powder formulation and a preparation method therefor. Specifically, the inhalable pharmaceutical powder formulation of the present disclosure comprises semaglutide and pharmaceutically acceptable excipients, wherein a mass median aerodynamic diameter of the pharmaceutical powder formulation is 0.5 ?m-10 ?m.

Abstract: The present invention relates to a nanostructured lipid hydrogel consisting of a three-dimensional network of interconnected sheets and vesicles comprising at least one zwitterionic phospholipid and water (between 70% and 97% by weight). The hydrogel does not comprise polymers, surfactants, fatty acids or fatty alcohols. The present invention also relates to the preparation method and use thereof, particularly as an active ingredient release system.

Abstract: The present disclosure is directed to an oil-in-water emulsion containing at least one hygroscopic ingredient and an edible oil. The emulsion has a water activity of less than about 0.6. The emulsion may be incorporated into an oral dosage form, including a capsule oral dosage form. The ingredients provided in the emulsion are capable of improving the health or well-being of a human or animal.

Abstract: The disclosure provides compositions of polymeric micelle complexes, as well as methods for preparing such compositions. Such compositions are suitable for pharmaceutical delivery of rnRNA or one or more zwitterionic agents to cell interior, and can be used in therapy and/or diagnosis, for example, for treating cancer, inflammation, microbial and viral infections, and metabolic disorders, as well as other diseases.

Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. hese liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.

Abstract: The present invention refers to a liposome comprising: a) a phospholipid; b) cholesterol (chol); c) a conjugate comprising a cholesterol moiety, a polyethylene glycol (PEG) moiety and a peptide moiety comprising a RGD sequence, wherein the PEG moiety is covalently attached to the cholesterol moiety by one end via a bond of the type alkyl ether and is covalently attached to the peptide moiety comprising the RGD sequence by the other end: d) a non-lipid cationic surfactant present in a percentage of less than 30% mol in respect to the total mol of the components of the liposome a), b), c) and d); and e) alpha-galactosidase (GLA) enzyme present in a ratio of micrograms of GLA in respect to the total milligrams of the components of the liposome a), b), c) and d) of between and including 2 to 35. It also refers to a pharmaceutical composition that comprises it and to the liposome or the pharmaceutical composition for use as a medicament, in particular for use in the treatment of Fabry disease.

Abstract: Liposomal formulations for delivery of hydrophilic agents to a tissue or tissue lumen, such the bladder, are described herein. These liposomal formulations can be administered to a subject in need thereof by various means, such as by instillation, to treat a tissue or tissue lumen, such as of the bladder.

Abstract: Disclosed is a nanocomplex, a preparation method therefor, and a use thereof. The nanocomplex comprises 0-60% a protein drug, 0.03-15% hyaluronic acid, 0.8-20% protamine, 35-95% lipid components, and 2.5-40% a apolipoprotein and/or a mimetic peptide thereof; the lipid components comprise an electrically neutral lipid and an anionic lipid; and the total amount of hyaluronic acid and protamine is 0.03-15%. The nanocomplex of the present invention provides a general-type carrier for protein drugs having different physicochemical properties (such as molecular weights of 10-255 KDa and PIs of 4-11), implements highly efficient intracellular, in vivo, and even in-brain delivery, utilized technology is universal in nature, and said invention can effectively solve the current problem of insufficient in vivo and in vitro transport of protein drugs (comprising a protein drug exceeding the molecular weight and PI of an embodiment).

Abstract: A device suitable for forming spherical particle clusters from fine powder is a device through which spherical particle clusters having a controlled particle size and a controlled hardness can be prepared from the fine powder by using a rolling granulation principle without adding any solution or solid binder. In particular, the device includes the following components: a) a preforming device for preforming particle clusters formed from fine powder, so that the particle clusters have a certain strength and shape while conveying the particle clusters to a next step at a certain speed; b) a spheroidizing device for further strengthening the particle clusters formed by a) the preforming device, so that the particle clusters have a higher sphericity and hardness; and c) a grading device for sieving the particle clusters spheroidized by b) the spheroidizing device to obtain particle clusters of different particle size ranges.

Abstract: The invention relates to solid pharmaceutical dosage forms comprising an extended release core comprising metformin hydrochloride and one or two immediate release coatings comprising linagliptin and/or empagliflozin.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

Abstract: According to some demonstrative embodiments, there is provided herein a probiotic granule comprising: a core comprising probiotic bacteria; and a single continuous coating layer coating said core comprising at least one an edible hydrophobic solid component such as fat, wax, phospholipid or a fatty acid having a melting point higher than 30° C.; at least one edible water-soluble polymeric stress absorber, dispersed within said hydrophobic solid component.

Abstract: The present disclosure provides a testis-targeted lycopene (LYC)/ZIF-90 nanocomposite and a preparation method and use thereof, belonging to the technical field of targeted drugs. In the present disclosure, a ZIF-90 metal-organic framework (MOF) material is combined with LYC through aldol condensation; when entering areas of inflammatory response and oxidative stress response, ZIF-90 may disintegrate and collapse in a slightly-acidic environment, releasing the LYC, thereby avoiding easy oxidation of the LYC and improving a bioavailability of the LYC; in addition, the disintegrated and collapsed ZIF-90 may also be utilized by organisms, thus greatly reducing a damage to the organisms. Moreover, the LYC/ZIF-90 nanocomposite is further loaded with follicle-stimulating hormone (FSH).

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: The present invention relates to a simple and convenient process for preparing solid lipid sustained release nanoparticles for berbamine delivery. The process involves preparation of nanoparticles by maintaining the pH of the aqueous or lipid phase so that high drug loading of 12-50% w/w with respect to the lipid matrix and high entrapment efficiency of more than 90% for berbamine in the solid lipid nanoparticles is achieved. The nanoformulation obtained by the process of the present invention has increased efficacy and exhibited any therapeutic property identical to free berbamine such as antiviral-cum-antibacterial agent for the treatment of microbial infections especially resistant Acinetobacter infections in treating diabetes and more specifically diabetes associated complications. Use may be extended to other diseases like COVID 19.

Abstract: Methods for preparing nucleic acid/lipid particles of an optimum particle size for efficient transfection of cells in vitro and in vivo local transfection are provided. The method is based on kinetic control of the nucleic acid/lipid nanoparticle assembly to prepare shelf-stable particles with defined sizes between about 50 nm and 1200 nm. The size-dependent characteristics of the nucleic acid/lipid particle-mediated transfection for the size range between 50 nm and 1200 nm also is provided.

Abstract: Disclosed herein are nanoparticles that include one or more cyclodextrin moieties crosslinked by a linker. The cyclodextrin moieties can complex therapeutic (e.g., anticancer) agents, and can be used to treat diseases such as cancer.